333455-13-3

Upstream product

• 333458-41-6 2-(2-cyano-3-methylamino-4-nitrophenyl)-2-methyl-3-oxobutyric acid ethyl ester 
• 333458-43-8 2-(4-amino-2-cyano-3-methylaminophenyl)-2-methyl-3-oxobutyric acid ethyl ester 
• 6590-95-0 2,6-dichlorophenylisothiocyanate 
• 333458-45-0 2-[4-cyano-2-(2,6-dichlorophenylamino)-3-methyl-3H-benzimidazol-5-yl]-2-methyl-3-oxobutyric acid ethyl ester 

Downstream Products

• 333455-25-7 2-(2,6-dichloro-phenylamino)-1,6-dimethyl-9-oxo-8,9-dihydro-1H-imidazo[4,5-h]isoquinoline-7-carbaldehyde 
• 333455-30-4 2-(2,6-Dichlorophenylamino)-1,6-dimethyl-7-vinyl-1,8-dihydro-imidazo[4,5-h]isoquinoline-9-one 
• 333455-32-6 2-(2,6-Dichlorophenylamino)-1,6-dimethyl-7-(1-hydroxyprop-2-en-1-yl)-1,8-dihydro-imidazo[4,5-h]isoquinolin-9-one 
• 333455-26-8 3-[2-(2,6-Dichlorophenylamino)-1,6-dimethyl-9-oxo-8,9-dihydro-1H-imidazo[4,5-h]isoquinolin-7-yl]-acrylic acid methyl ester 
• 333455-34-8 2-(2,6-dichlorophenylamino)-7-(1-acetoxyprop-3-en-1-yl)-1,6-dimethyl-1,8-dihydroimidazo[4,5-h]isoquinolin-9-one 
• 620590-67-2 2-(2,6-dichloro-phenylamino)-7-(1-hydroxy-2-trimethylsilanyl-ethyl)-1,6-dimethyl-1,8-dihydro-imidazo[4,5-h]isoquinolin-9-one 
• 333456-14-7 2-(2,6-Dichlorophenylamino)-7-(3-diethylaminopropen-1-yl)-1,6-dimethyl-1,8-dihydro-imidazo[4,5-h]-isoquinolin-9-one 
• 333458-57-4 2-(4-amino-5-bromo-2-cyano-3-methylaminophenyl)-2-methyl-3-oxobutyric acid ethyl ester 

Relevant academic research and scientific papers

INHIBITORS OF TYROSINE KINASES AND USES THEREOF

Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-rnediated diseases or conditions or tyrosine, kinase-dependent diseases or conditions are provided.

Heterocyclic compounds useful as inhibitors of tyrosine kinases

Disclosed are novel compounds of formula (I): wherein Ar1, Ra, R4, R5, X and Y are defined below, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases asso

Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: Orally active inhibitors of lck kinase

The tyrosine kinase p56lck (lck) is essential for T cell activation; thus, inhibitors of lck have potential utility as autoimmune agents. Our initial disclosure of a new class of lck inhibitors based on the phenylaminoimidazoisoquinolin-9-one showed reaso

Heterocyclic compounds useful as inhibitors of tyrosine kinases

Disclosed are novel compounds of formula (I): wherein Ar1, Ra, R4, R5, X and Y are defined below, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases asso

Isoquinolinone synthesis by SNAr reaction: A versatile route to imidazo[4,5-h]isoquinolin-9-ones

Reaction of 2-chlorobenzonitriles with β-ketoesters in an SNAr reaction, followed by cyclization in acid provides a versatile route to isoquinolones. Starting from 2,6-dichloro-3-nitrobenzonitrile 7, sequential displacement of the chlorines by